Comparative Pharmacology
Head-to-head clinical analysis: ENJAYMO versus FABHALTA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENJAYMO versus FABHALTA.
ENJAYMO vs FABHALTA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ENJAYMO (sutimlimab-jome) is a monoclonal antibody that binds to complement component C1s and inhibits the activation of the classical complement pathway. This prevents the destruction of red blood cells, platelets, and endothelial cells by the complement system.
Fabhalta (iptacopan) is a complement factor B inhibitor that binds to factor B and prevents the formation of the alternative pathway C3 convertase, thereby inhibiting complement alternative pathway activation.
600 mg subcutaneous injection once weekly for 4 weeks, followed by 900 mg every 2 weeks.
200 mg orally twice daily.
None Documented
None Documented
6-8 days (terminal half-life); prolonged due to FcRn binding, allowing monthly dosing
Terminal elimination half-life is approximately 8 hours (range 6-10 hours), supporting twice-daily dosing for sustained complement inhibition.
Renal: <1% unchanged; primarily eliminated via FcRn-mediated catabolism; no biliary/fecal excretion data
Primarily renal (approximately 70% as unchanged drug) and biliary/fecal (approximately 30% as metabolites).
Category C
Category C
Complement Inhibitor
Complement Inhibitor